Results for tag: "Iclusig"

Iclusig (ponatinib) is a targeted therapy drug used to treat certain types of leukemia. It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Iclusig is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also approved for the treatment of adults with T315I-positive CML and Ph+ ALL who have already received other TKI treatments. Iclusig is a part of the larger leukemia drug market, which includes a variety of treatments such as chemotherapy, radiation therapy, stem cell transplants, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells, and they are often used in combination with other treatments. Some companies in the Iclusig market include Takeda Pharmaceuticals, Novartis, Pfizer, and Bristol-Myers Squibb. Show Less Read more